These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 16777410)

  • 1. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
    Petrov KG; Zhang YM; Carter M; Cockerill GS; Dickerson S; Gauthier CA; Guo Y; Mook RA; Rusnak DW; Walker AL; Wood ER; Lackey KE
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4686-91. PubMed ID: 16777410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
    Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
    Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
    Kitano Y; Suzuki T; Kawahara E; Yamazaki T
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.
    Waterson AG; Petrov KG; Hornberger KR; Hubbard RD; Sammond DM; Smith SC; Dickson HD; Caferro TR; Hinkle KW; Stevens KL; Dickerson SH; Rusnak DW; Spehar GM; Wood ER; Griffin RJ; Uehling DE
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1332-6. PubMed ID: 19208477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.
    Li S; Guo C; Zhao H; Tang Y; Lan M
    Bioorg Med Chem; 2012 Jan; 20(2):877-85. PubMed ID: 22182581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
    Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Amino-6-arylamino-pyrimidine-5-carbaldehyde hydrazones as potent ErbB-2/EGFR dual kinase inhibitors.
    Xu G; Abad MC; Connolly PJ; Neeper MP; Struble GT; Springer BA; Emanuel SL; Pandey N; Gruninger RH; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4615-9. PubMed ID: 18653333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Acton DG; Ballard P; Bradbury RH; Cross D; Ducray R; Germain H; Hudson K; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Ross HS; Smith R; Trigwell CB; Vautier M; Wright L
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1799-803. PubMed ID: 18313293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
    Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
    Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
    Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
    Ban HS; Onagi S; Uno M; Nabeyama W; Nakamura H
    ChemMedChem; 2008 Jul; 3(7):1094-103. PubMed ID: 18465761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
    Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
    J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
    Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
    Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases.
    Lee KI; Park Y; Park SJ; Hwang JH; Lee SJ; Kim GD; Park WK; Lee S; Jeong D; Kong JY; Kang HK; Cho H
    Bioorg Med Chem Lett; 2006 Feb; 16(3):737-42. PubMed ID: 16321529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.